Smo Mutations Do Not Seem To Drive Multifocal Relapse Of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation.

Nicole Basset Seguin,Meriem Ighilahriz,M. Benfodda,Nadem Soufir,Samia Mourah,Nicolas Dumaz,Maxime Battistella,Fanny Bouquet,Ariel Savina

JOURNAL OF CLINICAL ONCOLOGY（2018）

引用 0|浏览21

暂无评分

摘要

e21559Background: Vismodegib , a selective Hh pathway inhibitor that targets Smoothened (SMO) is a major therapeutic breakthrough for locally advanced (la) or metastatic BCC. During treatment some ...

查看译文

关键词

advanced basal cell carcinoma,smo mutations,vismodegib discontinuation,multifocal relapse

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要